ArticleEmerging infectious diseases2024
Clostridium butyricum Bacteremia Associated with Probiotic Use, Japan.
Article in Emerging infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Strategies to Maximize the Benefits of Evidence-Based Enteral Nutrition: A Narrative Review.Nutrients · 2025Pooled it
- Gut microbiome dynamics in acute infectious diarrhea: A conceptual framework from acute dysbiosis toward precision restoration (Review).Experimental and therapeutic medicine · 2026Review
- Clinical analysis of 16 patients withNew microbes and new infections · 2026Article
- Probiotics in Autoimmune Disease: Strain-specific Mechanisms and Therapeutic Perspectives.Clinical reviews in allergy & immunology · 2026Review
- Clinical Outcomes of Metronidazole Monotherapy Versus Metronidazole PlusBiotech (Basel (Switzerland)) · 2026Article
- Severe Bacteremia Caused byDEN open · 2026Article
- The role ofFrontiers in immunology · 2026Review
- PostbioticFrontiers in immunology · 2026Article
- Clostridium butyricum Regulates the Inflammatory and Immunoregulatory Pathway Through NFKB1 in Colorectal Cancer Treatment.Probiotics and antimicrobial proteins · 2026Article
- Case Series of Bacteremia Associated with Probiotic Use in Children after Cardiac Surgery, China.Emerging infectious diseases · 2026Review
- Research progress and controversies in the treatment of functional constipation-related depression with probiotics and prebiotics: a narrative review.Frontiers in pharmacology · 2026Review
- The gut‑skin axis: Emerging insights in understanding and treating skin diseases through gut microbiome modulation (Review).International journal of molecular medicine · 2025Review
- Role of intestinal SCFAs homeostasis in the hepatoprotective effect of Clostridium butyricum in T2DM.NPJ biofilms and microbiomes · 2025Article
- Harnessing Probiotics to Combat Candidiasis: Mechanisms, Evidence, and Future Directions.Journal of fungi (Basel, Switzerland) · 2025Review
- The Majority ofOpen forum infectious diseases · 2025Article
- Efficacy ofMicroorganisms · 2025Review
- Survival and Morphological Changes ofMicroorganisms · 2025Article
- Probiotic treatment in an intensive care unit: a narrative review.Journal of intensive care · 2025Review
- Exploring the Potential of Novel Animal-Origin Probiotics as Key Players in One Health: Opportunities and Challenges.International journal of molecular sciences · 2025Review
- Pterostilbene attenuates intestinal barrier damage and secondary liver oxidative stress in a murine model ofFood & function · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium butyricum, a probiotic commonly prescribed in Asia, most notably as MIYA-BM (Miyarisan Pharmaceutical Co., Ltd.; https://www.miyarisan.com), occasionally leads to bacteremia. The prevalence and characteristics of C. butyricum bacteremia and its bacteriologic and genetic underpinnings remain unknown. We retrospectively investigated patients admitted to Osaka University Hospital during September 2011-February 2023. Whole-genome sequencing revealed 5 (0.08%) cases of C. butyricum bacteremia among 6,576 case-patients who had blood cultures positive for any bacteria. Four patients consumed MIYA-BM, and 1 patient consumed a different C. butyricum-containing probiotic. Most patients had compromised immune systems, and common symptoms included fever and abdominal distress. One patient died of nonocclusive mesenteric ischemia. Sequencing results confirmed that all identified C. butyricum bacteremia strains were probiotic derivatives. Our findings underscore the risk for bacteremia resulting from probiotic use, especially in hospitalized patients, necessitating judicious prescription practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.